These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 36061184)

  • 1. Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer.
    Xiao C; Yang L; Jin L; Lin W; Zhang F; Huang S; Huang Z
    Front Genet; 2022; 13():962028. PubMed ID: 36061184
    [No Abstract]   [Full Text] [Related]  

  • 2. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
    Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
    Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.
    Yang L; Zhang Y; Wang Y; Jiang P; Liu F; Feng N
    Front Pharmacol; 2022; 13():938134. PubMed ID: 36210836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and immunological role of FDX1 in pan-cancer: an in-silico analysis.
    Liu Z; Miao J
    Sci Rep; 2023 May; 13(1):7926. PubMed ID: 37193786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Cuproptosis-Related Prognostic Model and the Hub Gene
    Zhang K; Yang W; Zhang Z; Ma K; Li L; Xu Y; Qiu J; Yu C; Zhou J; Cai L; Gong Y; Gong K
    J Oncol; 2022; 2022():2124088. PubMed ID: 36536785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker.
    Zhang C; Zeng Y; Guo X; Shen H; Zhang J; Wang K; Ji M; Huang S
    Front Genet; 2022; 13():923737. PubMed ID: 35991547
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic and immune regulating roles of YIF1B in Pan-Cancer: a potential target for both survival and therapy response evaluation.
    Liu J; Chen Z; Zhao P; Li W
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32648580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD).
    Wang L; Cao Y; Guo W; Xu J
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):15-24. PubMed ID: 36173462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cuproptosis-related gene
    Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
    Front Immunol; 2022; 13():999823. PubMed ID: 36225932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer.
    Li X; Dai Z; Liu J; Sun Z; Li N; Jiao G; Cao H
    Front Genet; 2022; 13():969856. PubMed ID: 36226187
    [No Abstract]   [Full Text] [Related]  

  • 12. Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma.
    Lu H; Zhou L; Zhang B; Xie Y; Yang H; Wang Z
    Front Med (Lausanne); 2022; 9():939776. PubMed ID: 36523779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.
    Yao Y; Chen H; Lou M; Chen T
    Front Genet; 2023; 14():1071694. PubMed ID: 36755576
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
    Chen Y
    Front Genet; 2022; 13():912037. PubMed ID: 35937995
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator
    Zeng S; Zhang H; Zhang D; Hu X; Song L
    Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel prognostic signature of cuproptosis-related genes and the prognostic value of FDX1 in gliomas.
    Zhu H; Wan Q; Tan J; Ouyang H; Pan X; Li M; Zhao Y
    Front Genet; 2022; 13():992995. PubMed ID: 36579333
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1.
    Quan Y; Li W; Yan R; Cheng J; Xu H; Chen L
    Front Oncol; 2023; 13():1168769. PubMed ID: 37361595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDX1 expression predicts favourable prognosis in clear cell renal cell carcinoma identified by bioinformatics and tissue microarray analysis.
    Huang X; Wang T; Ye J; Feng H; Zhang X; Ma X; Wang B; Huang Y; Zhang X
    Front Genet; 2022; 13():994741. PubMed ID: 36186457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comprehensive Prognostic and Immune Analysis of SLC41A3 in Pan-Cancer.
    Liu J; Zhang S; Dai W; Xie C; Li JC
    Front Oncol; 2020; 10():586414. PubMed ID: 33520701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated profiling identifies ferredoxin 1 as an immune-related biomarker of malignant phenotype in glioma.
    Xie D; Huang H; Guo Y; Jiang Z; Kuang Y; Huang H; Liu W; Wang L; Xin Z; Wang B; Ren C; Jiang X
    Heliyon; 2024 Mar; 10(5):e26976. PubMed ID: 38463788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.